Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLOMID vs OSPHENA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.
Selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and lipid metabolism, and as an estrogen antagonist on breast and uterine tissue. It mimics estrogen's effects on bone by reducing bone resorption and increasing bone mineral density.
Treatment of ovulatory dysfunction in women desiring pregnancy (FDA approved),Off-label: treatment of male infertility (oligospermia)
Treatment of osteoporosis in postmenopausal women at high risk of fracture,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis,Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
60 mg orally once daily with food.
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
The terminal elimination half-life of ospemifene is approximately 26 hours (range 22-39 hours), supporting once-daily dosing.
Hepatic via CYP3A4 and CYP2D6; undergoes enterohepatic circulation; terminal half-life ~5-7 days
Extensively metabolized in the liver via glucuronidation (UGT1A8, UGT1A10, UGT2B7) and to a lesser extent by cytochrome P450 (CYP3A4, CYP2C19). Undergoes enterohepatic recycling. Half-life is approximately 5.7 days.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
Following oral administration, 50% of a radiolabeled dose is excreted in urine and 35% in feces within 168 hours, primarily as glucuronide conjugates; <1% is excreted unchanged.
Highly protein bound (>99%), primarily to albumin.
Ospemifene is >99% bound to plasma proteins, primarily albumin.
Not well-characterized; limited data suggest a large Vd (>100 L) due to extensive tissue distribution.
The apparent volume of distribution (Vd/F) is approximately 2.4 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 50% due to first-pass metabolism.
Absolute bioavailability is approximately 30% after oral administration due to first-pass metabolism.
No specific adjustment required; use caution in severe impairment (Cr Cl <30 m L/min) as data limited.
No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (Cr Cl <30 m L/min).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no adjustment recommended, but monitor liver function.
Child-Pugh A: no adjustment; Child-Pugh B: not recommended; Child-Pugh C: contraindicated.
Not indicated for use in children; safety and efficacy not established.
Safety and efficacy not established; no specific dosing guidelines.
Not indicated for postmenopausal women. Use not recommended in elderly due to lack of efficacy in anovulation.
No specific dose adjustment; monitor for dysphagia and esophageal adverse effects.
None
Increased risk of venous thromboembolic events (including deep vein thrombosis and pulmonary embolism) and death due to stroke. Use is contraindicated in women with active or past history of venous thromboembolism.
Ovarian hyperstimulation syndrome (OHSS),Ovarian enlargement,Visual disturbances (especially with prolonged use),Multiple pregnancy (increased risk),Ectopic pregnancy,Ovarian cancer risk (theoretical, based on prolonged use)
Increased risk of venous thromboembolic events and stroke; consider risk-benefit in women at risk for these events. May cause hot flashes and leg cramps. Use with caution in patients with hepatic impairment or history of cholestasis. Not recommended for use in premenopausal women. Discontinue if prolonged immobilization occurs. Monitor lipid profile; may cause small reductions in HDL cholesterol.
Pregnancy (Category X),Liver disease or dysfunction,Undiagnosed abnormal vaginal bleeding,Ovarian cyst or enlargement not due to polycystic ovary syndrome,Hypersensitivity to clomiphene or components
Active or past history of venous thromboembolism (DVT, PE, retinal vein thrombosis), pregnancy (can cause fetal harm), women who are or may become pregnant, nursing mothers, patients with hypersensitivity to raloxifene or any component of the formulation.
No specific food interactions. Avoid grapefruit as it may alter metabolism (theoretical due to CYP3A4 involvement).
No specific food interactions; take with food to minimize gastrointestinal side effects.
Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs during the first trimester. Second and third trimester risks are not well studied due to contraindication, but theoretical risks include ovarian hyperstimulation syndrome (OHSS) effects on pregnancy.
Ospemifene is contraindicated in pregnancy. Based on its mechanism as a selective estrogen receptor modulator (SERM) and animal studies showing embryotoxicity and teratogenicity, there is potential for fetal harm. First trimester exposure may increase risk of congenital anomalies; second/third trimester exposure may cause urogenital tract abnormalities and endocrine disruption.
Safety in breastfeeding is not established. Clomiphene may reduce milk production. The M/P ratio is unknown. It is generally not recommended during breastfeeding.
No data on human milk excretion. Ospemifene may suppress lactation due to estrogenic effects. M/P ratio unknown. Avoid breastfeeding during treatment and for at least 2 weeks after last dose.
No dose adjustments are relevant as clomiphene is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are not applicable due to contraindication.
No dose adjustments studied; contraindicated in pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered clearance) may occur but no data to guide dosing.
Monitor ovarian size via ultrasound to reduce risk of ovarian hyperstimulation syndrome (OHSS). Limit course to 3-6 cycles due to increased risk of ovarian tumors. Check pregnancy test before each cycle. Use with caution in liver disease.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women. Avoid in women with estrogen-dependent neoplasia, unexplained genital bleeding, or prior thromboembolic events. Monitor for endometrial hyperplasia because uterine stimulation can occur. Not for use in premenopausal women.
Take exactly as prescribed, typically 50 mg daily for 5 days starting on day 5 of menstrual cycle.,Report abdominal pain, bloating, nausea, or weight gain (possible OHSS).,Avoid alcohol due to hepatotoxicity risk.,Most pregnancies occur within first 3 cycles; consider alternative after 6 cycles.,May cause visual disturbances; report blurred vision or spots.
Take daily with food to reduce nausea.,Do not take if you have a history of blood clots, breast cancer, or uterine cancer.,Report any unusual vaginal bleeding, breast pain, or leg swelling immediately.,May cause hot flashes, vaginal discharge, or muscle spasms.,Use proper lubricants during intercourse; this medicine does not protect against STIs.,Continue regular pelvic exams and mammograms as recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLOMID vs OSPHENA, answered by our medical review team.
CLOMID is a Selective Estrogen Receptor Modulator that works by Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.. OSPHENA is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and lipid metabolism, and as an estrogen antagonist on breast and uterine tissue. It mimics estrogen's effects on bone by reducing bone resorption and increasing bone mineral density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLOMID and OSPHENA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLOMID is: 50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.. The standard adult dose of OSPHENA is: 60 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLOMID and OSPHENA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLOMID is classified as Category C. Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs. OSPHENA is classified as Category C. Ospemifene is contraindicated in pregnancy. Based on its mechanism as a selective estrogen receptor modulator (SERM) and animal studies showing embryotoxicity and teratogenicity, t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.